Sugi Predict

Sugi Predict / Compounds / SCHEMBL21997660

SCHEMBL21997660

SCHEMBL21997660

COC(=O)c1ccc(-n2cc([N+](=O)[O-])c(C(F)F)n2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ VCAM1 P19320 1/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ KDM4E B2RXH2 3/20 0.40
▸ POLB P06746 2/20 0.40
▸ MAPT P10636 4/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ ALDH1A1 P00352 3/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ TP53 P04637 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ ERN1 O75460 1/20 0.39
▸ RECQL P46063 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21069279 0.86 MAPK1 (0.42) SMN1; SMN2MAPTMEN1KMT2AALDH1A1
SCHEMBL21070791 0.84 MAPK1 (0.39) SMN1; SMN2CA12CA1CA2CA9
SCHEMBL21069418 0.83 SIRT6 (0.41) SMN1; SMN2CA12CA1CA2CA9
SCHEMBL21071090 0.81 SMN1; SMN2 (0.44) SMN1; SMN2VCAM1CA12CA1CA2
SCHEMBL21070798 0.81 SMN1; SMN2 (0.52) SMN1; SMN2VCAM1CA12CA1CA2
SCHEMBL21069438 0.80 PTGS1 (0.42) SMN1; SMN2CA12CA1CA2CA9
SCHEMBL21070025 0.80 HSD17B10 (0.42) SMN1; SMN2CA12CA1CA2CA9
SCHEMBL31211820 0.79 SMN1; SMN2 (0.42) SMN1; SMN2KDM4EPOLBMAPTMEN1
SCHEMBL23946141 0.79 ALDH1A1 (0.40) SMN1; SMN2CA12CA1CA2CA9
SCHEMBL21997169 0.78 PTGS2 (0.38) SMN1; SMN2CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 — — EP disclosed
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-20250011325-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-01-09 — — US disclosed
EP-4472967-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-12-11 — — EP disclosed
US-12091411-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-09-17 — — US disclosed
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-07-18 — — US disclosed
US-20230365562-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-11-16 — — US disclosed
US-20230365562-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-11-16 — — US disclosed
US-20230365562-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-11-16 — — US disclosed
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 — — US disclosed
WO-2023147594-A2 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 — — US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 — — US disclosed
EP-3886904-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2021-10-06 — — EP disclosed
CN-113423427-A IRAK degrading agents and uses thereof 凯麦拉医疗公司 2021-09-21 — — CN disclosed
US-11117889-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2021-09-14 — — US disclosed
WO-2020113233-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-06-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365562-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 SMN1; SMN2 2647/4885VCAM1 3606/4885CA12 4583/4885
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 SMN1; SMN2 2647/4885VCAM1 3606/4885CA12 4583/4885
US-20250011325-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 SMN1; SMN2 2647/4885VCAM1 3606/4885CA12 4583/4885
US-11117889-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 SMN1; SMN2 2647/4885VCAM1 3606/4885CA12 4583/4885
US-11352350-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 SMN1; SMN2 2647/4885VCAM1 3606/4885CA12 4583/4885
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 SMN1; SMN2 2647/4885VCAM1 3606/4885CA12 4583/4885
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 SMN1; SMN2 2647/4885VCAM1 3606/4885CA12 4583/4885
US-12091411-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 SMN1; SMN2 2647/4885VCAM1 3606/4885CA12 4583/4885
US-11807636-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 SMN1; SMN2 2647/4885VCAM1 3606/4885CA12 4583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.